Bacteria Strain PAHM4 Differs in Bronchiectasis, CF Patient Lungs

In a recent study entitled “Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains,” researchers investigated the mechanisms the bacteria Continue reading Bacteria Strain PAHM4 Differs in Bronchiectasis, CF Patient Lungs

Ex-vivo Lung Perfusion Technology Opens New Possibilities In One Of The Most Problematic Areas Of Lung Transplant Surgery

http://cysticfibrosisnewstoday.com/2015/10/13/trial-shows-ex-vivo-lung-filtering-technique-cuts-transplant-rejection/

Originally published in Cystic Fibrosis News Today
By Charles Moore

Exciting new research, partly funded by the U.K. Cystic Fibrosis Trust and the Robert Luff Foundation and announced at the Trust’s U.K. CF Conference last week, shows promising results in reconditioning poorly functioning donor lungs Continue reading Ex-vivo Lung Perfusion Technology Opens New Possibilities In One Of The Most Problematic Areas Of Lung Transplant Surgery

Discovery of Iron Metabolism-associated Gene Could Lead to New P. aeruginosa Treatments for Cystic Fibrosis Inhibition of PA4834 could contribute to the efficient eradication of P. aeruginosa in Cystic Fibrosis patients

http://cysticfibrosisnewstoday.com/2015/10/19/discovery-iron-metabolism-associated-gene-lead-new-p-aeruginosa-treatments-cystic-fibrosis/

Originally published in Cystic Fibrosis News Today
By Ana Pamplona, PhD

A new study entitled “A novel siderophore system is essential for the growth of Pseudomonas aeruginosa in airway mucus” published in the Scientific Reports journal by researchers from the PLUS Project for Medical Science and Yonsei Continue reading Discovery of Iron Metabolism-associated Gene Could Lead to New P. aeruginosa Treatments for Cystic Fibrosis Inhibition of PA4834 could contribute to the efficient eradication of P. aeruginosa in Cystic Fibrosis patients

PTC submits EU application for Translarna for cystic fibrosis

The European Medicines Agency (EMA) has validated the submission of a variation for a new indication for PTC Therapeutics’ Translarna (ataluren) for the treatment of nonsense mutation cystic fibrosis (nmCF) for patients not taking Continue reading PTC submits EU application for Translarna for cystic fibrosis

Air pollution and traffic linked to deaths and organ rejection in lung transplant patients

Researchers have shown for the first time that lung transplant patients in Europe who live on or near busy roads with high levels of air pollution are more likely to die or to experience chronic organ rejection, Continue reading Air pollution and traffic linked to deaths and organ rejection in lung transplant patients

Arno Therapeutics’ AR-13 Shows Promise as Potential New Cystic Fibrosis Therapeutic Option for Serious Bacterial Infections

http://cysticfibrosisnewstoday.com/2015/09/25/arno-therapeutics-ar-13-shows-promise-potential-new-cystic-fibrosis-therapeutic-option-serious-bacterial-infections/

First published by Cystic Fibrosis News Today
By Charles Moore

Flemington, New Jersey based clinical stage biopharmaceutical company Arno Therapeutics, Inc. has announced data from a preclinical study demonstrating that its drug candidate AR-13, an analogue of Arno’s AR-12 infectious disease Continue reading Arno Therapeutics’ AR-13 Shows Promise as Potential New Cystic Fibrosis Therapeutic Option for Serious Bacterial Infections